Sofosbuvir improves renal safety in patients with chronic hep C

May 11, 2018

(HealthDay)—Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up, according to a study published online May 7 in the Journal of Clinical Pharmacy and Therapeutics.

Thalia Medeiros, from the Universidade Federal Fluminense in Niterói, Brazil, and colleagues evaluated renal biomarkers among 94 chronic hepatitis C patients treated with sofosbuvir therapy. Urine samples were collected at the end of therapy, after 12 weeks sustained , and one year post-treatment.

The researchers found that 98.9 percent of patients reached sustained virological response. In patients with (GFR) ≥45 mL/min/1.73 m² there was significant improvement in renal biomarkers, as indicated by a progressive increase in mean GFR values until one year. There was no evidence of tubular dysfunction. There was no change in renal biomarkers among patients with baseline GFR <45 mL/min/1.73 m².

"In a 'real-life experience' of a Brazilian center, sofosbuvir therapy appears to guarantee renal safety for patients with C followed until one year after treatment," the authors write.

Explore further: HBV reactivation seen with DAA treatment of chronic hep C

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

HBV reactivation seen with DAA treatment of chronic hep C

March 13, 2017
(HealthDay)—For patients with chronic hepatitis C (CHC) treated with direct-acting antivirals (DAAs), hepatitis B virus (HBV) reactivation may occur in those with current HBV infection, according to a study published online ...

Most patients prefer oral dual therapy in chronic hepatitis C

September 20, 2016
(HealthDay)—For patients with chronic hepatitis C (CHC), most prefer oral therapy with sofosbuvir (SOF) and ribavirin (RBV) versus triple therapy involving pegylated interferon (PegIFN), according to a study published online ...

Sofosbuvir plus ledipasvir seems effective for HCV genotype 1

November 4, 2014
(HealthDay)—For patients with chronic hepatitis C virus genotype 1 (HCV GT-1) infection who are ineligible for interferon therapy, and who relapsed after sofosbuvir and ribavirin treatment, sofosbuvir plus ledipasvir is ...

HCV treatment found safe and effective in individuals with kidney disease

September 7, 2017
A new study indicates that direct-acting antiviral therapy is safe and effective in patients with chronic kidney disease (CKD) and Hepatitis C virus (HCV) infection. The study, which appears in an upcoming issue of the Clinical ...

Sustained virological response to oral hepatitis C virus treatment associated with reduced mortality in Italian cohort

April 13, 2018
Patients with chronic hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) after direct-acting antiviral agent (DAA) treatment have lower all-cause mortality, according to a real-world study ...

Glecaprevir-pibrentasvir effective treatment for HCV genotypes 1, 3

January 31, 2018
(HealthDay)—Once-daily treatment with glecaprevir-pibrentasvir appears safe and effective for the treatment of hepatitis C virus (HCV) genotype 1 or 3, according to a study published in the Jan. 25 issue of the New England ...

Recommended for you

Tibetan sheep highly susceptible to human plague, originates from marmots

August 16, 2018
In the Qinghai-Tibet plateau, one of the region's highest risk areas for human plague, Himalayan marmots are the primary carriers of the infectious bacterium Y. pestis. Y. pestis infection can be transmitted to humans and ...

Autoimmunity plays role in development of COPD, study finds

August 16, 2018
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information ...

Reliable point-of-care blood test can help prevent toxoplasmosis

August 16, 2018
A recent study, performed in Chicago and Rabat, Morocco, found that a novel finger-prick test for infection with the parasite Toxoplasma gondii during pregnancy—and many other potential applications—is 100 percent sensitive ...

Scientists identify nearly 200 potential tuberculosis drug targets

August 16, 2018
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost ...

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.